Literature DB >> 30761461

The Curve of Optimal Sample Size (COSS): A Graphical Representation of the Optimal Sample Size from a Value of Information Analysis.

Eric Jutkowitz1, Fernando Alarid-Escudero2, Karen M Kuntz3, Hawre Jalal4.   

Abstract

Value of information (VOI) analysis quantifies the opportunity cost associated with decision uncertainty, and thus informs the value of collecting further information to avoid this cost. VOI can inform study design, optimal sample size selection, and research prioritization. Recent methodological advances have reduced the computational burden of conducting VOI analysis and have made it easier to evaluate the expected value of sample information, the expected net benefit of sampling, and the optimal sample size of a study design ([Formula: see text]). The volume of VOI analyses being published is increasing, and there is now a need for VOI studies to conduct sensitivity analyses on VOI-specific parameters. In this practical application, we introduce the curve of optimal sample size (COSS), which is a graphical representation of [Formula: see text] over a range of willingness-to-pay thresholds and VOI parameters (example data and R code are provided). In a single figure, the COSS presents summary data for decision makers to determine the sample size that optimizes research funding given their operating characteristics. The COSS also presents variation in the optimal sample size given variability or uncertainty in VOI parameters. The COSS represents an efficient and additional approach for summarizing results from a VOI analysis.

Entities:  

Mesh:

Year:  2019        PMID: 30761461      PMCID: PMC6556417          DOI: 10.1007/s40273-019-00770-z

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  34 in total

1.  Prioritizing Future Research on Allopurinol and Febuxostat for the Management of Gout: Value of Information Analysis.

Authors:  Eric Jutkowitz; Fernando Alarid-Escudero; Hyon K Choi; Karen M Kuntz; Hawre Jalal
Journal:  Pharmacoeconomics       Date:  2017-10       Impact factor: 4.981

2.  Expected value of information and decision making in HTA.

Authors:  Simon Eckermann; Andrew R Willan
Journal:  Health Econ       Date:  2007-02       Impact factor: 3.046

3.  Optimal clinical trial design using value of information methods with imperfect implementation.

Authors:  Andrew R Willan; Simon Eckermann
Journal:  Health Econ       Date:  2010-05       Impact factor: 3.046

4.  Determining optimal sample sizes for multi-stage randomized clinical trials using value of information methods.

Authors:  Andrew Willan; Matthew Kowgier
Journal:  Clin Trials       Date:  2008       Impact factor: 2.486

5.  Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007-2008.

Authors:  Yanyan Zhu; Bhavik J Pandya; Hyon K Choi
Journal:  Arthritis Rheum       Date:  2011-10

6.  Gout epidemiology: results from the UK General Practice Research Database, 1990-1999.

Authors:  T R Mikuls; J T Farrar; W B Bilker; S Fernandes; H R Schumacher; K G Saag
Journal:  Ann Rheum Dis       Date:  2005-02       Impact factor: 19.103

7.  Time and expected value of sample information wait for no patient.

Authors:  Simon Eckermann; Andrew R Willan
Journal:  Value Health       Date:  2007-12-17       Impact factor: 5.725

8.  Cost-effectiveness of screening for ovarian cancer amongst postmenopausal women: a model-based economic evaluation.

Authors:  Ben Kearns; Jim Chilcott; Sophie Whyte; Louise Preston; Susi Sadler
Journal:  BMC Med       Date:  2016-12-06       Impact factor: 8.775

9.  Strategies for efficient computation of the expected value of partial perfect information.

Authors:  Jason Madan; Anthony E Ades; Malcolm Price; Kathryn Maitland; Julie Jemutai; Paul Revill; Nicky J Welton
Journal:  Med Decis Making       Date:  2014-01-21       Impact factor: 2.583

10.  Value of Information Analysis Informing Adoption and Research Decisions in a Portfolio of Health Care Interventions.

Authors:  Haitham W Tuffaha; Louisa G Gordon; Paul A Scuffham
Journal:  MDM Policy Pract       Date:  2016-07-07
View more
  3 in total

1.  Calculating the Expected Value of Sample Information in Practice: Considerations from 3 Case Studies.

Authors:  Anna Heath; Natalia Kunst; Christopher Jackson; Mark Strong; Fernando Alarid-Escudero; Jeremy D Goldhaber-Fiebert; Gianluca Baio; Nicolas A Menzies; Hawre Jalal
Journal:  Med Decis Making       Date:  2020-04-16       Impact factor: 2.583

2.  A Need for Change! A Coding Framework for Improving Transparency in Decision Modeling.

Authors:  Fernando Alarid-Escudero; Eline M Krijkamp; Petros Pechlivanoglou; Hawre Jalal; Szu-Yu Zoe Kao; Alan Yang; Eva A Enns
Journal:  Pharmacoeconomics       Date:  2019-11       Impact factor: 4.981

3.  Computing the Expected Value of Sample Information Efficiently: Practical Guidance and Recommendations for Four Model-Based Methods.

Authors:  Natalia Kunst; Edward C F Wilson; David Glynn; Fernando Alarid-Escudero; Gianluca Baio; Alan Brennan; Michael Fairley; Jeremy D Goldhaber-Fiebert; Chris Jackson; Hawre Jalal; Nicolas A Menzies; Mark Strong; Howard Thom; Anna Heath
Journal:  Value Health       Date:  2020-05-27       Impact factor: 5.725

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.